Table 2.

Base-case cost-effectiveness and cost-utility results^a.

	Costs per person (USD)	Incremental costs per 100,000 people screened (USD)	Years without blindness per person	Incremental years without blindness per 100,000 people screened	QALYb per person	Incremental quality-adjusted life years per 100,000 people screened	ICERc (USD)	ICURd (USD)
AIe-assisted model	3182.47	–8,289,840.65	9.80	–3121.32	6.748	–544.78	2553.39	15,216.96
Manual grading	3265.37	N/Af	9.83	N/A	6.753	N/A	N/A	N/A

^aCosts, years without blindness, and quality-adjusted life years are lifetime values per person, whereas incremental costs, incremental years without blindness, incremental cost-effectiveness ratio, incremental quality-adjusted life years, and incremental cost-utility ratio are calculated against the manual grading–based telemedicine screening scenario per 100,000 people screened.

^bQALY: quality-adjusted life year.

^cICER: incremental cost-effectiveness ratio.

^dICUR: incremental cost-utility ratio.

^eAI: artificial intelligence.

^fN/A: not applicable.